The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
WT1 molecular assessment combined with flow cytometry increases the prognostic value of pre transplant MRD in AML
The presence of Minimal Residual Disease (MRD) before allogeneic Stem Cell Transplantation (SCT) has been shown to be associated with poor outcomes in patients with Acute Myeloid Leukemia (AML).1 Multicolor Flow Cytometry (MFC) is recognized as a reliable tool for evaluation of MRD. Furthermore, Wilms Tumor 1 (WT1) gene expression is the most standardized molecular MRD marker in AML.
In a Letter to the Editor of Haematologica on 11th May 2017, Fabio Guolo, University of Genoa, Genoa, and colleagues discuss results from their retrospective study which analyzed the role of pre-transplant combined MFC-molecular MRD assessment as a predictor of post-transplant relapse risk.2,3
WT1 gene expression and MRD evaluation by MFC was analyzed in bone marrow samples from 224 consecutive AML patients who received allogenic-SCT in either First or Second Complete Remission (CR1/2) at the IRCCS AOU San Martino-IST, University of Genoa between January 2004 and January 2014.
The key results of the study were:
- 3-year Cumulative Incidence (CI) of relapse in patients that were MFC negative/WT1 negative (24/224), MFC positive/ WT1 negative (150/224) and MFC positive/ WT1 positive (50/224) were 8.7%, 23.1% and 51.9% respectively; P < 0.0001
- 3-year Overall Survival (OS) in patients that were MFC/WT1 negative, MFC positive/ WT1 negative and MFC positive/ WT1 positive were 73.5%, 60% and 36.7% respectively; P < 0.0001
In summation, combined molecular (WT1- based) and MFC assessment of pre-transplant MRD can accurately predict relapse risk in AML patients.
References